RE:RE:Tax inversion articlesAt this point I don't care - just make a decision that is sound for shareholders and continue on it. With the price the way it is now, in a year it will at least double. The US government slapped this down right before the merger was going to be finalized. Coincidence? If Pozen and Tribute could move this forward just a little bit quicker then it wouldn't of been issue.
Make a decision, move forward to making the company focus on pharma, provide shareholder value. How you do it doesn't matter as much as doing it at this point.